NEUROSCIENCE - Centered at understanding brain circuitry, function, and disorder, the Neuroscience research housed in the Department is formed by a group of neuroscientists taking holistic approaches from DNA manipulation, receptor functioning, synaptic remodeling, to brain circuitry visualization. Multidiscipline studies include developmental neuroscience, neural stem cells, neuroimmunology, neuropathology, and neuroimaging. A common thread of this collective neuroscience studies is in-depth neuroanatomical approaches combined with cutting-edge tools e.g. epigenetics, optogenetics, glutamate uncaging, single-cell & patch-clamp recording, fMRI, brain imaging sound perception, and computational neuroscience.
RENAL BIOLOGY - The research programs of the Renal Biology Group are built on a foundation in cell and molecular biology, pathology, biological imaging, and biophysics. Our goal is to understand the cell and tissue level mechanisms at play in the development and treatment of chronic renal disease, with emphasis on polycystic kidney disease and nephrolithiasis. Current projects focus on epigenetic factors in the progression of PKD, pathogenesis of Meckel Syndrome, pathogenesis of tubulointerstitial fibrosis, Matrix Bone Disorder in chronic kidney disease, proteomics and biomarkers of human vascular calcification, pathogenesis of kidney stone formation, and bioeffects and mechanisms of shock wave action in shock wave lithotripsy.
SKELETAL BIOLOGY - There is a long tradition of outstanding research in skeletal biology at the Indiana University School of Medicine, which has been a center for studies on osteoporosis and arthritis since the late 1960's. Initially, much of the work was clinically-oriented, and was performed primarily by physician scientists. The skeletal biology faculty in the Department have worked closely with biomedical engineers who were brought to campus in part by the Biomechanics and Biomaterials Research Center, in which the Department played a prominent role. Over the next decade, the Department continued to expand its skeletal biology faculty, and to work closely with scientists at Eli Lilly and Company who were developing several therapeutic agents (since approved and now marketed) for the treatment of osteoporosis.